A primary tumor rarely kills, but secondary tumors do and currently there is no therapy specifically designed to prevent early metastasis formation in prostate cancer. Swedish biotech RhoVac AB hopes its lead asset RV001, a vaccine that is in Phase IIb trials targeting the RhoC protein, will shortly offer such patients a drug that minimizes the risk of the cancer returning in metastatic form after curative intent treatment of the primary tumor, the biotech’s CEO told Scrip.
Sweden’s RhoVac Aims To Become An M&A Target
Late 2021 RV001 Phase IIb Data May Offer Trigger, CEO Says
RhoVac is in mid-stage trialing of a vaccine based on the RhoC protein that aids the metastatic potential of cancer cells and their ability to migrate and infiltrate other tissue. The Swedish biotech’s CEO believes the drug is a potential blockbuster.
More from Clinical Trials
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
More from R&D
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
• By
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.